TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07544056: A Randomized, Controlled, Open-label, Multi-center, Phase IIb/III Clinical Study to Evaluate BEBT-209 Plus Carboplatin and Gemcitabine Versus Carboplatin Plus Gemcitabine in Locally Advanced or Metastatic Triple-Negative

Sponsor: BeBetter Med Inc · Phase: PHASE2/PHASE3 · Area: ONCOLOGY · Target Enrollment: 446 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$18,036,480

Rescue Site Savings

+$11,892,804

Unlock Full NCT07544056 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07544056 Rescue Dossier →